Skip to main content

Table 3 Cytokines and coagulation parameters in 74 COVID-19 patients stratified according to high (≥ median) versus low (< median) IP-10

From: IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19

  Total (N = 74) IP-10 P
Low (N = 34) High (N = 40)
n Median (IQR) n Median (IQR) n Median (IQR)
IL-1β, pg/mL 29 5.0 (5.0–5.0) 11 5.0 (5.0–5.0) 18 5.0 (5.0–7.3) 0.253
IL-2R, U/mL 30 1055.5 (464.5–1609.5) 12 784.0 (362.8–1256.3) 18 1311.5 (721.0–1957.0) 0.099
IL-6, pg/mL 48 74.2 (17.0–157.5) 23 26.3 (9.6–95.9) 25 114.8 (54.6–343.1) 0.001
IL-8, pg/mL 29 51.7 (12.5–114.7) 11 19.5 (10.1–51.7) 18 78.8 (22.3–156.0) 0.018
IL-10, pg/mL 29 11.4 (5.0–20.1) 11 5.0 (5.0–9.0) 18 16.8 (8.5–36.4) 0.001
TNFα, pg/mL 27 12.7 (7.5–28.7) 10 8.6 (5.5–10.7) 17 16.2 (8.9–37.1) 0.021
Prothrombin time (PT), s 71 15.9 (14.9–18.2) 32 15.6 (14.7–17.3) 39 16.9 (15.3–19.0) 0.029
Prothrombin activity (PTA), % 71 69.0 (55.0–80.0) 32 71.5 (60.0–80.8) 39 63.0 (51.0–74.0) 0.025
International normalized ratio (INR) 71 1.26 (1.15–1.49) 32 1.24 (1.14–1.41) 39 1.36 (1.20–1.58) 0.026
Fibrinogen (FIB), g/L 71 4.2 (3.1–5.2) 32 4.0 (3.5–4.7) 39 4.6 (2.5–5.7) 0.675
Activated partial thromboplastin time (APTT), s 71 44.5 (39.3–52.6) 32 43.0 (37.5–50.2) 39 46.8 (40.7–57.4) 0.069
Thrombin time (TT), s 71 15.3 (14.5–16.5) 32 15.1 (14.4–15.8) 39 15.8 (14.9–17.7) 0.016
d-Dimer, μg/mL FEU 71 3.85 (1.68–13.46) 32 2.52 (1.32–8.56) 39 5.73 (2.33–18.00) 0.056
Fibrin degradation products (FDP), μg/mL 30 17.2 (6.2–68.6) 13 9.4 (4.0–52.3) 17 17.7 (13.6–130.5) 0.089
Antithrombin (AT), % 34 80.5 (65.5–88.5) 16 83.0 (66.8–92.3) 18 78.5 (62.5–85.8) 0.48
  1. Bold indicates the statistically significant values (P < 0.05)